News >

Expert Recaps Adjuvant Advancements in HER2+ Breast Cancer

Angelica Welch
Published: Thursday, May 24, 2018

Haythem Y. Ali, MD

Haythem Y. Ali, MD
The 2 biggest advancements in the treatment of patients with HER2-positive breast cancer in the last year were FDA approvals in the adjuvant setting, according to Haythem Y. Ali, MD.

In July 2017, the FDA approved neratinib (Nerlynx) for the extended adjuvant treatment of patients with early-stage, HER2-positive breast cancer following postoperative trastuzumab (Herceptin). This approval was based on data from the phase III ExteNET trial and the phase II CONTROL trial.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication
x